Kazia Therapeutics Ltd KZIA
Kazia Therapeutics Ltd (Nasdaq: KZIA) is an oncology drug developer. Its lead program, Paxalisib (GDC-0084), is in Phase 2 for Glioblastoma and other brain cancers (brain metastases, DIPG/DMG, breast cancer). Its next catalyst on record is Paxalisib (MSKCC brain metastases Phase 1): Clinical study report (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Paxalisib (MSKCC brain metastases Phase 1) — Clinical study report (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Paxalisib - glioblastoma (Global Coalition for Adaptive Research Phase II/III) | Glioblastoma | small molecule | Phase 2 |
| Paxalisib - PNOC022 (with ONC201) | Diffuse midline glioma / DIPG | small molecule | Phase 2 |
| Paxalisib - brain metastases (Alliance, Dana-Farber, MSKCC) | Brain metastases, HER2+ breast cancer brain metastases | small molecule | Phase 2 |
| Paxalisib - advanced TNBC with pembrolizumab (company-sponsored Phase 1b) | Stage IV triple-negative breast cancer | small molecule | Phase 1 |
| EVT801 | Advanced solid tumors (VEGFR3 inhibitor) | small molecule | Phase 1 |
Recent results and decisions
- Sep 22, 2026started Licensee Sovargen dosed first patient in a Phase 1b/2a trial of paxalisib in mTORopathy-related epilepsies, triggering a $2 million milestone to Kazia.
has dosed the first patient in a Phase 1b/2a clinical trial evaluating paxalisib for the treatment of intractable epilepsy associated with focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC)
Filing - Aug 27, 2026positive Investor presentation cites clinical benefit in 6/6 Stage IV TNBC patients on paxalisib combination (1 complete response, 4 partial responses, 1 stable disease) in the Phase 1b study.
6/6 Stage IV TNBC Patients with Clinical Benefit
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.